Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab bioavailability study with on-body injector
NCT06937619Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration at 140 days, Time to Maximum Concentration at 140 days and 6 more. Started Apr 2025; status: completed.
02
Drugs
risankizumab
Beyond the preview
Go deeper on NCT06937619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937619.